Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 6
Submit an article Journal homepage
509
Views
49
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Olanzapine: review of safety 2008

Joshua T Kantrowitz Fellow, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
, MD &
Leslie Citrome Professor of Psychiatry, New York University School of Medicine, Director, Clinical Research and Evaluation Facility Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA +1 845 398 5595; +1 845 398 5483; [email protected]
, MD MPH
Pages 761-769 | Published online: 04 Nov 2008

Bibliography

  • Zyprexa. Anon. 2008. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed 2008 May 21]
  • Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-52
  • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
  • Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge, UK: Cambridge University Press; 2008
  • Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-78
  • Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1021-8
  • Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48(2):157-65
  • Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
  • Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/briefing/2008-4338b1-03-Lilly.pdf [Last accessed 2008 June 8]
  • Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
  • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
  • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
  • Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
  • Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch of Gen Psychiatry 2006;63(10):1079-87
  • Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
  • Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13(1):28-42
  • Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
  • Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
  • Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71
  • Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88
  • Brown EB, McElroy SL, Keck PEJ, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2003;67(7):1025-33
  • Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
  • Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55
  • Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7
  • Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60(12):1218-26
  • Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67(11):1747-53
  • Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
  • Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189(2):259-66
  • Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86(1-3):234-43
  • Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26(5):453-61
  • Lieberman JA, McEvoy JP, Perkins DO, et al. Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]. Eur Neuropsychopharmacol 2005;15(3 Suppl):S526
  • McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(18 Suppl):47-56
  • Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007;22(3):145-52
  • Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702
  • Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
  • Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18
  • Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
  • Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
  • Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-62
  • Dossenbach M, Pachecho Z, Toledo D, et al. Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]. Eur Neuropsychopharmacol 2006;16(4 Suppl):S407-8
  • Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17(4):235-44
  • Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62(2):92-100
  • Kinon BJ, Volavka J, Stauffer VL, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol 2008;28(4):392-400
  • Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006;26(3):316-20
  • Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102(1-3):230-40
  • Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120(2):18-33
  • Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US. Diabetes Care 2001;24(2):412
  • Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997 – 2004. Psychiatr Serv 2006;57(8):1132-9
  • Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70(1):19-26
  • Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36(1):62-7
  • Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996;53(1):25-31
  • Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697-701
  • Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(6 Suppl):47-55
  • Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68(11):1682-90
  • Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6
  • Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(10):1837-47
  • Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162(8):1535-8
  • Smith RC, lindenmayer A, Buga A, et al. Metabolic changes during 5 months treatment with olanzapine or risperidone: preliminary results from randomized trial [abstract]. Schizophr Bull 2005;31(2):570
  • Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572-8
  • Beasley CMJ, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23(6):582-94
  • Citrome L, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41(10):1593-603
  • Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006;26(5):504-7
  • Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64
  • Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19(6 Suppl):102-9
  • Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64(5):598-4
  • Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
  • Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract 2007;61(12):1960-2
  • Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract 2008;62(5):837-40
  • Yang S-Y, Kao Yang Y-H, Chong M-Y, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based Study. Clin Pharmacol Ther 2007;81(4):586-94
  • Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
  • Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6
  • Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66(9):1130-3
  • Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005;53(8):1374-9
  • Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care 2007;13(Suppl):1-12
  • Svestka J, Synek O, Tomanová J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007;28(6):881-8
  • Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Clin Psychopharmacol 2008;22(2 Suppl):46-55
  • Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65(1):57-61
  • Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2007;22(2 Suppl):90-7
  • Schiavi RC, Stimmel BB, Mandeli J, et al. Diabetes, psychological function and male sexuality. J Psychosom Res 1995;39(3):305-14
  • Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55(9):406-13
  • Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol 2008;22(2 Suppl):38-45
  • Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
  • Goder R, Fritzer G, Gottwald B, et al. Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. Pharmacopsychiatry 2008;41(3):92-9
  • Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008;69(2):302-9
  • Citrome L. Atypical antipsychotics, elderly patients, and mortality risk. South Med J 2007;100(1):964-5
  • Beasley CMJ, Tollefson GD, Tran PV. Safety of Olanzapine. J Clin Psychiatry 1997;58(10 Suppl):13-7
  • Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today 2003;39(7):551-7
  • Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome – a case review. Hum Psychopharmacol 2003;18(4):301-9
  • Norgard NB, Stark JE. Olanzapine-Associated Neuroleptic Malignant Syndrome. Pharmacotherapy 2006;26(8):1180-2
  • Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870-6
  • Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003;28(4):253-61
  • Citrome L, Kantrowitz J. Using antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008;8(7):1079-91
  • Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60(8):933-40
  • Martinez-Arán A, Vieta E, Chengappa KN, et al. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord 2008;10(5):566-79
  • Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23(10):2551-7
  • Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/ 2006/12/17/business/17drug.html [Last accessed 2008 Sept 3]
  • Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.